Press Release 17 June 2009 

e-Therapeutics plc (AIM: ETX), the systems biology drug discovery company, announces that on 18 March 2009, the Self Invested Pension Plan of John Cordiner acquired, in aggregate, 5,000 ordinary shares of 0.1p each in the Company (“Ordinary Shares”) at an average price of 34p per share. Following this acquisition, John Cordiner and his Self Invested Pension Plan have in aggregate an interest in 367,060 Ordinary Shares, which represents 0.6 % of the current issued share capital of the Company.

                                                     - Ends -

For further information:

e-Therapeutics plc
www.etherapeutics.co.uk

Malcolm Young
malcolm@etherapeutics.co.uk
+44 (0) 191 233 1317
    

Nominated Advisor:

WH Ireland
Katy Mitchell
katy.mitchell@wh-ireland.co.uk
+44 (0)113 394 6628

Broker:

Cornhill Asset Management
Tom Whitehead
tomw@cornhillassetmanagement.com
+44 (0) 20 7645 8327

Andrew Houchin
andrewh@cornhillassetmanagement.com
+44 (0) 20 7743 6468

Media enquiries:

Abchurch
www.abchurch-group.com
Heather Salmond
heather.salmond@abchurch-group.com
Tel: +44 (0) 20 7398 7704

Stephanie Cuthbert
stephanie.cuthbert@abchurch-group.com
Tel: +44 (0) 20 7398 7718


Simone Alves
simone.alves@abchurch-group.com
Tel: +44 (0) 20 7398 7728

Notes to Editors

 e-Therapeutics plc is a systems biology drug discovery company. It has developed proprietary computational systems to swiftly and accurately analyse and predict how medicines interact with cells in the body. This optimises the probability of identifying drug candidates with desirable efficacy and low toxicity. The Company applies its novel, systematic approach to three areas of activity:

•     discovery of new drugs;
•     discovering novel uses for existing drugs; and
•     analysis of the interactions between different drugs.

Amongst e-Therapeutics’ pipeline of compounds in development are novel antibiotics that have been shown to kill the “superbug” MRSA, and a novel cancer chemotherapy that has been shown to kill malignant cells at safe doses in a very short time. Other candidate therapies in development are targeted at atherosclerosis, asthma and depression. The Company is currently in negotiation with a number of pharmaceutical companies, and is progressing the preclinical and clinical development of these products.

 

For further information on e-Therapeutics visit www.etherapeutics.co.uk.